Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELACS-T2D empagliflozin after acute coronary syndrome
ACTRN12621000355875Phase 4Terminated
- Sponsor
- Fiona Stanley Hospital
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of empagliflozin in type 2 diabetes mellitus (T2DM) and acute coronary syndrome (ACS) (2 arms), sponsored by Fiona Stanley Hospital. Primary endpoints: Left ventricular diastolic function and Left ventricular mass indexed to body surface area. Started Oct 2021; status: terminated.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)acute coronary syndrome (ACS)
Beyond the preview
Go deeper on ACTRN12621000355875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000355875.